04. February 2020 | 05:50 CET
Aurora Cannabis, EXMceuticals, Tilray - Cannabis development in Portugal
From the street to the clinic. Cannabis had the image of an illegal street drug in most rich countries since the prohibition in the USA in the 1930s. Although cannabis has been used as a medicinal plant for more than 1,000 years, the past decades have been marked by other pharmaceutical products. The market and attitudes towards cannabis are now changing. Doctors, patients, companies and investors see opportunities to profit from this development.
time to read:
ISIN: CA30207T1049 , CA05156X1087 , US88688T1007
Education is the key to success
Education and research are often the beginning of a success story. In order for development to progress, knowledge and education are an elementary basis for medical change with cannabis. Doctors, patients and companies must work together to test and evaluate the effects of cannabis in medicine.
With increasing experience and information in databases the acceptance of cannabis in medicine will increase. Thus the use of medical cannabis preparations can be suggested by physicians or simply demanded by patients.
Improvement of the quality of life
The use of and experiences with cannabis products are characterized by objective and subjective characteristics. For example, a cannabis product may cause a patient to sleep much better but not to feel any improvement in pain relief. The bottom line, however, is that the quality of life has subjectively increased due to improved sleep.
Such developments in practice ensure that cannabis products are accepted in medicine. In this context, however, it is important that patients have easy access to medical cannabis products and also that doctors know what they are prescribing for which therapies.
Opportunities for investors
Also the companies invest in the development of the cannabis market and here especially experience counts. Aurora Cannabis, EXMceuticals and also Tilray have different approaches and strategies to conquer the market for cannabis products.
For investors there is the opportunity to participate in the listed companies to be part of it. Even if the share prices of most cannabis companies have been declining in recent months, the trend in use and therapy will continue. It will probably only be a matter of time when this development will be reflected in the stock market prices again.
Portugal as cannabis centre
EXMceuticals, a manufacturer of high quality cannabis extracts for use in the pharmaceutical and nutraceutical industry as well as in therapy and cosmetics, announced yesterday that Prf. Dr. Eurico Castro Alves has been appointed to the company's advisory board.
Commenting on the appointment, Jonathan Summers, CEO of the company, said: "He and EXM share a common goal to establish Portugal as a centre for medical Cannabis healthcare and science. The next step is to have in operation, and licensed, a high-quality ingredients factory that will produce to medical standards and have many industrial applications.”